GlassScriptPhysician profile
Ada I Arias
NPI 1306848171
$4,795.66
in general payments reported to CMS, 2019-2025
23 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $683 · 2021: $217 · 2022: $209 · 2023: $279 · 2024: $346 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.84 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,101.33 | 2019-2025 | Nucala, Rotarix, Bexsero |
| Novartis Pharmaceuticals Corporation | $649.70 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $508.80 | 2019-2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $394.80 | 2019-2020 | |
| Philips North America LLC | $388.03 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.11 | 2019-2025 | Jascayd |
| Genentech USA, INC. | $317.38 | 2019-2020 | |
| Mylan Specialty L.P. | $226.62 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $220.81 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $102.56 | 2019 | |
| Pfizer INC. | $102.43 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.91 | 2019 | |
| Jazz Pharmaceuticals INC. | $64.85 | 2019-2020 | |
| Insmed, INC. | $55.65 | 2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $36.94 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.34 | 2019 | |
| Chiesi USA, INC. | $31.32 | 2019-2020 | |
| Intuitive Surgical, INC. | $29.14 | 2023 | Da Vinci Surgical System |
| Viatris Specialty LLC | $20.99 | 2025 | Yupelri |
| Sandoz INC. | $16.76 | 2025 | Treprostinil |
| Circassia INC. | $14.41 | 2019 | |
| United Therapeutics Corporation | $11.50 | 2021 | |
| Allergan, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.